Manuel Valdivieso, MD
Manuel Valdivieso, M.D., is a clinical professor of internal medicine at the University of Michigan and Senior Executive Officer at SWOG (previously the Southwest Oncology Group). As a senior executive officer, Dr. Valdivieso is responsible for quality assurance and international initiatives for SWOG. The Group's international affiliations have expanded under Dr. Valdivieso's tenure, and SWOG has in the past two years welcomed members from Canada, Mexico, and South Korea. Dr. Valdivieso continues to build on clinical trials and collaboration in countries throughout Central and South America. He works collaboratively with Dr. Laurence Baker on a Latin America initiative that had led to four National Cancer Institutes of Latin America to becoming members of SWOG (Brazil, Colombia, Mexico and Peru). Dr. Valdivieso earned his M.D. from San Marcos University Medical School in Lima, Peru. His professional experience includes lengthy affiliation with MD Anderson Cancer in Houston, where he completed his fellowship in medical oncology/developmental therapeutics and as faculty became Internist and Professor of Medicine and leader in the Thoracic Oncology Program. Thereafter, he led the Division of Hematology Oncology at Wayne State University in Detroit, and served as chief medical officer for the Karmanos Cancer Institute.
Lung cancer and H. pylori infection and cancer in Latin America. Participant in SWOG study of three antibiotic regimens in six Latin American countries and is presently conducting a primary prevention pilot study of water contamination with H. pylori in Peru. This work is conducted in collaboration with investigators at the U of M and in Peru
Education and Training
|Medical School, San Marcos University, Lima, Peru|
|Internship, Hospital General de CHULEC in Peru and Cook County Hospital in Chicago, Illinois|
|Residency, Cook County Hospital, Chicago, IL|
|Fellowship, Cook County Hospital (Hematology) and
University of Texas MD Anderson Cancer Center (Oncology)
Honors & Awards
|2007||Cited in Best Doctors in America|
|2011||American Cancer Society Distinguished Service Award|
|2011||President, Peruvian American Medical Society|
Greenberg, E.R., Anderson, G.L., Morgan, D.R., Torres, J., Chey, W.D., Bravo, L.E., Dominguez, R.L., Ferreccio, C., Herrero, R., Lazcano-Ponce, E.C., Meza-Montenegro, M.M., Pena, E.M., Pena, E.M., Salazar-Martinez, E., Correa, P., Martinez, M.E., Valdivieso, M., Goodman, G.E., Baker, L.H. 14-day triple, 5-day concomitant and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomized trial. Published on line by The Lancet on July 20, 2011. DOI: 10.1016/S0140-6736 (11) 60825-8.
Valdivieso, M., Kujawa, A.M., Jones, T., Baker, L.H. Cancer Survivors in the United States: A Review of the Literature and a Call to Action. Int. J. Med. Sci 2012, 9 (2012; 9(2). doi: 10.7150/ijms.3827).
Morgan, R.D., Torres, J., Sexton, R., Herrero, R., Salazar-Martinez, E., Greenberg, E.R., Bravo, L.E., Dominguez, R.L., Ferreccio, C., Lazcano-Ponce, E.C., Meza-Montenegro, M.M., Peña, E.M., Peña, R., Correa, P., Martinez, M.E., Chey, W.D., Valdivieso, M., Anderson, G.L., Goodman, G.E., Crowley, J.J., Baker, L.H. Risk of Recurrent Helicobacter pylori Infection 1 Year After Initial Eradication Therapy in 7 Latin American Communities. JAMA, 2013; Vol 309; No 6: 578 – 586.